Compare LENZ & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LENZ | IPHA |
|---|---|---|
| Founded | 2019 | 1999 |
| Country | United States | France |
| Employees | N/A | 163 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.8M | 189.5M |
| IPO Year | 2021 | N/A |
| Metric | LENZ | IPHA |
|---|---|---|
| Price | $5.57 | $1.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $44.00 | $5.75 |
| AVG Volume (30 Days) | ★ 610.6K | 14.1K |
| Earning Date | 05-06-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,088,000.00 | N/A |
| Revenue This Year | $50.42 | $180.36 |
| Revenue Next Year | $197.16 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.73 | $1.18 |
| 52 Week High | $50.19 | $2.63 |
| Indicator | LENZ | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 26.32 | 58.62 |
| Support Level | N/A | $1.73 |
| Resistance Level | $10.42 | $1.90 |
| Average True Range (ATR) | 0.43 | 0.08 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 0.56 | 76.43 |
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.